Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Albumin-Related Ratios Investigated in HBV-Associated Decompensated Cirrhosis

By LabMedica International staff writers
Posted on 25 Mar 2022

Decompensated cirrhosis (DeCi) is a terminal liver disease characterized by various complications and associated with dramatically reduced survival. More...

Liver transplantation is the most effective therapy for hepatitis B virus (HBV)-DeCi.

Serum albumin is considered a biomarker of malnutrition–inflammation syndrome, and there is emerging data that hypoalbuminemia is related to worse survival in intensive care unit patients. Albumin has multiple functions and plays important roles in liver disease severity, progression, and prognosis.

Clinical Laboratorians at The Second Affiliated Hospital Zhejiang University (Zhengzhou, China) enrolled a total of 161 HBV-DeCi patients. The main causes of admission were ascites (n = 120, 74.5%), gastrointestinal bleeding (n = 36, 22.5%), hepatorenal syndrome (n = 22, 14.0%), and encephalopathy (n = 10, 6.2%). Twenty-four patients (15.0%) had more than one feature of decompensation at presentation.

Laboratory variables (total bilirubin, total protein, albumin, blood urea nitrogen [BUN], creatinine, aspartate aminotransferase, alanine aminotransferase, C-reactive protein [CRP], white blood count [WBC], platelet count, hemoglobin, neutrophil count, plasma D-dimer, and international normalized ratio [INR]), and HBV-DNA levels, as well as hepatitis B e antigen status, were recorded at admission. Severity of liver disease and prognosis were assessed using the Model for End-Stage Liver Disease (MELD) score.

The investigators reported that a total of 29 (18.0%) patients had died 30 days after admission. The prognostic roles of C-reactive protein-to-albumin ratio (CAR), D-dimer-to-albumin ratio (DAR), prothrombin time-international normalized ratio-to-albumin ratio (PTAR), neutrophil count-to-albumin (NAR), and blood urea nitrogen-to-albumin ratio (BAR) in HBV-DeCi were different. CAR, PTAR, NAR, and BAR were significantly higher in non-survivors compared with survivors. However, DAR did not differ between the two groups. The predictive power of BAR was superior to that of the other four albumin-related biomarkers and similar to that of MELD score. On multivariate analysis, BAR and MELD score were identified as independent prognostic factors, and the combination of BAR and MELD score may improve the prognostic accuracy in HBV-DeCi.

The authors concluded that they had evaluated five albumin-related ratios (CAR, DAR, PTAR, NAR, and BAR) for the prediction of mortality in HBV-DeCi patients. Their study suggests that BAR can be a simple, effective, and useful prognostic tool to predict poor outcomes in HBV-DeCi patients and that use of a combination of BAR and MELD score can improve the prognostic accuracy. The study was published on March 17, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
The Second Affiliated Hospital Zhejiang University 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.